In a patient on 70 mg Vyvanse (lisdexamfetamine) who does not achieve adequate symptom control with methylphenidate, what are the recommended next steps?

What to Do When Methylphenidate is Ineffective

If methylphenidate fails to provide adequate symptom control after an appropriate trial (adequate dose for 6 weeks), switch to lisdexamfetamine (Vyvanse) as the next-line treatment. 1

Treatment Algorithm After Methylphenidate Failure

First Step: Switch to Lisdexamfetamine

• Lisdexamfetamine should be preferred over non-stimulants (atomoxetine, guanfacine) when methylphenidate is ineffective 1
• This recommendation is based on the different mechanism of action: methylphenidate primarily blocks dopamine/norepinephrine reuptake, while amphetamines (like lisdexamfetamine) additionally promote neurotransmitter release from presynaptic terminals 2, 3
• The prodrug formulation of lisdexamfetamine provides consistent conversion to active d-amphetamine in the blood, potentially offering more predictable therapeutic effects 4

Dosing Strategy for Lisdexamfetamine

• Start at 30 mg every morning 5
• Titrate by 10-20 mg weekly based on response and tolerability 5
• Target dose range: 30-70 mg daily (maximum 70 mg/day) 5
• Higher doses (50-70 mg) may be particularly beneficial for patients with greater baseline symptom severity, especially for hyperactive-impulsive symptoms 6

Evidence Supporting This Approach

The guideline evidence is clear and consistent: European NICE guidelines specifically recommend switching to lisdexamfetamine in patients who have undergone a 6-week trial of methylphenidate at adequate dose without sufficient benefit 2, 1. This represents Level 1 guideline evidence.

Research data supports this approach across different patient populations:

• Children previously symptomatic on methylphenidate (ADHD-RS-IV >18) showed comparable improvements to treatment-naïve patients when switched to lisdexamfetamine 7
• Response to lisdexamfetamine was similar regardless of prior ADHD medication history 8
• Real-world European data shows that 79.6% of patients prescribed lisdexamfetamine had previous methylphenidate exposure, confirming this as standard clinical practice 9

Important Clinical Considerations

Before initiating lisdexamfetamine:

• Assess for cardiac disease (structural abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease) - these are contraindications 5
• Screen for risk factors for mania or psychosis 5
• Evaluate family history and assess for tics or Tourette's syndrome 5
• Check renal function: maximum dose is 50 mg/day in severe renal impairment, 30 mg/day in ESRD 5

Monitor during treatment:

• Blood pressure and heart rate regularly 5
• Growth parameters (height and weight) in pediatric patients - treatment interruption may be needed if growth suppression occurs 5
• Digital changes (peripheral vasculopathy/Raynaud's phenomenon) 5
• Emergence or worsening of psychiatric symptoms 5

Expected Adverse Events Profile

The most common adverse events (≥5% and twice placebo rate) include 5:

• Decreased appetite (62.4% in real-world data) 10
• Insomnia (28.7%) 10
• Dry mouth
• Irritability/aggression (26.1%) 10
• Weight decrease (21.1%) 10
• Anxiety
• Nausea

Critical point: Most adverse events are actually less frequent with lisdexamfetamine compared to methylphenidate when patients switch 10. This is important because adverse effects are the most common reason (70%) for methylphenidate discontinuation 10.

If Lisdexamfetamine Also Fails

If lisdexamfetamine at optimized doses (up to 70 mg) proves ineffective or intolerable:

• Consider non-stimulant options: atomoxetine or guanfacine 1
• In Japan's treatment algorithm, if both first-line agents fail, lisdexamfetamine is actually positioned as third-line, with atomoxetine and guanfacine as second-line 2 - however, this differs from Western guidelines and reflects cultural/regulatory factors rather than efficacy data

Common Pitfalls to Avoid

1. Inadequate methylphenidate trial: Ensure the patient truly had an adequate trial (appropriate dose for 6 weeks) before switching 1
2. Underdosing lisdexamfetamine: Don't stop at 30 mg - most patients require 50-70 mg for optimal response 6
3. Premature discontinuation: Allow 2-4 weeks for full therapeutic effect, though some improvement should be evident earlier
4. Missing cardiac screening: This is a critical safety step that cannot be skipped 5
5. Ignoring comorbidities: Psychiatric comorbidities may require adjustment of the treatment approach 10

Real-World Persistence Data

Among children observed for at least 1 year after lisdexamfetamine initiation, 41.3% continued treatment for a year or longer 10. Discontinuation rates ranged from 22.8% to 70.6% across European countries over 5 years 9, with adverse effects (74.4%) and lack of efficacy (34.7%) being the primary reasons for stopping 10.